Amira Pharmaceuticals Announces Appointment of First Chief Executive Officer

01-Aug-2007

Amira Pharmaceuticals announced that the company has appointed Robert F. Baltera, Jr., as the company's first chief executive officer, effective immediately.

Before becoming Amira's CEO, Baltera held a number of senior management positions at Amgen, most recently as vice president of corporate and contract manufacturing. A scientist by training, Baltera joined Amgen at the beginning of his career as a research associate but quickly moved to the operations side of the business, working in finance, product development and commercial operations. He successfully used that collective experience to serve as team leader responsible for the approval of Kineret(TM) in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.

Baltera has a master's of business administration from the Anderson School at UCLA. He earned his bachelor's degree in microbiology and a master's degree in genetics from The Pennsylvania State University.

Other news from the department people

Most read news

More news from our other portals

Last viewed contents

Novartis and Gen-Probe Agree to Extend and Expand Blood Screening Collaboration - Companies will work together to protect the world's supply of donated blood from infectious diseases until 2025

Cell Therapeutics' subsidiary PanGenex introduces technology for high-throughput, cell-based screening of new cancer targets - Technology described at international scientific conference

LION Bioscience, Ltd. Signs Collaboration Agreement with European Molecular Biology Laboratory

DiagnoCure partner launches new prostate cancer test in Europe

On the trail of cancer stem cells - What goes on inside and between individual cells during the very earliest stages of tumor development?

On the trail of cancer stem cells - What goes on inside and between individual cells during the very earliest stages of tumor development?

BIOBASE übernimmt Proteome Inc. von Incyte Corp. - Internationale Firmenübernahme im Bereich Bioinformatik

Icon Genetics and Novoplant announce broad license agreement

Researchers identify non-culturable microbes from bloodstream infections

Scientists Discover New Molecular Markers for Testicular Cancer - Researchers in the Netherlands use new technology from Applied Biosystems to identify different expression patterns of microRNA molecules in normal and cancerous cells

Hospira Announces $2 Billion Agreement to Acquire Mayne Pharma

MOLOGEN: Executive Board orients towards new commercial tasks

DeveloGen and Scientists from IPK Gatersleben Publish Data on Key Trigger for Regenerating Insulin Producing Cells - Study Provides Additional Support in Fight to Treat Diabetes